How Is The Polymyositis Market Expected To Grow At 6.1% CAGR Over 2025–2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Polymyositis Market Be Worth By 2029?
Over the past few years, the polymyositis market has experienced significant growth. It’s projected to expand from $1.65 billion in 2024 to $1.74 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.7%. This robust increase during the historical period is fueled by several factors: enhanced access in emerging regions, the escalated use of prednisone, the rising acceptance of methotrexate for symptom management, the growing adoption of TNF inhibitors, and the heightened utilization of antibody testing.
Looking ahead, the polymyositis market is set to experience strong growth, estimated to reach $2.21 billion by 2029 with a 6.1% CAGR. This growth during the forecast period is likely to be fuelled by factors such as the expansion of telemedicine, the increased usage of remote monitoring and immunosuppressants, the growing use of stem cell therapy, and the rising popularity of biosimilars. Other significant trends that could dominate the forecast period include the role of artificial intelligence in drug discovery, advancements in targeted therapies, the creation of innovative immunomodulators, increased research in regenerative medicine, and the inclusion of big data.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22104&type=smp
What External And Internal Drivers Are Influencing The Polymyositis Market?
The polymyositis market is anticipated to see substantial growth due to the rising occurrence of autoimmune diseases. These diseases are characterized by the body’s immune system erroneously attacking its own healthy cells, tissues, or organs, leading to inflammation and damage. The incidence of such diseases is growing as certain genetic variations can trigger an overly active immune response, thereby making individuals more prone to mistakenly attacking their own tissues. Factors such as infections, stress, and lifestyle, coupled with genetic predisposition, are contributing to the escalation in cases of autoimmune disorders. Polymyositis aids in better comprehending autoimmune diseases by showcasing how a faulty immune system leads to muscle inflammation, thus offering insights into the mechanisms and possible therapeutic interventions for related disorders. For instance, as per Versorgungsatlas.de, a German organization, they reported that in 2022, out of 73,241,305 insured people, 6,304,340 were diagnosed with at least one autoimmune disease. This equates to a raw prevalence rate of 8.61% in November 2024. Hence, the escalating occurrence of autoimmune diseases is propelling the growth of the polymyositis market.
What Segmentation Insights Are Provided In The Polymyositis Market Research?
The polymyositismarket covered in this report is segmented –
1) By Type: Idiopathic Polymyositis; Dermatomyositis; Inclusion Body Myositis; Overlapping Myositis Syndromes
2) By Diagnosis: Physical Examination; Muscle Biopsy; Electromyography (EMG); Blood Tests; Magnetic Resonance Imaging (MRI)
3) By Treatment: Immunosuppressant; Immunoglobulins; Corticosteroids; Alkylating agents; Monoclonal Antibodies
4) By Distribution Channel: Offline; Online
5) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy
Subsegments:
1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis; Virus-Associated Polymyositis
2) By Dermatomyositis: Classic Dermatomyositis; Amyopathic Dermatomyositis; Juvenile Dermatomyositis
3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis; Hereditary Inclusion Body Myopathy
4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE); Polymyositis with Rheumatoid Arthritis (RA); Polymyositis with Systemic Sclerosis; Polymyositis with Mixed Connective Tissue Disease (MCTD)
Which Trends Are Likely To Redefine Growth Paths In The Polymyositis Market?
Leading companies in the polymyositis market are exploring stem cell therapies to enhance treatment effectiveness and slow disease progression. Stem cell therapy uses umbilical cord-derived stem cells with immunomodulatory and anti-inflammatory effects, showing promise for autoimmune diseases like polymyositis. For example, in December 2024, RESTEM, a US clinical-stage biotech company, received Orphan Drug Designation from the FDA for its program using umbilical cord outer lining stem cells to treat polymyositis and dermatomyositis by modulating immune response and reducing muscle inflammation. Early trials indicate safety and potential to reduce steroid dependence.
Who Are The Leading Companies Driving The Polymyositis Market?
Major companies operating in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/polymyositis-global-market-report
Which Geographic Regions Are Creating Strong Demand In The Polymyositis Market?
North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=22104&type=smp
Browse Through More Reports Similar to the Global Polymyositis Market 2025, By The Business Research Company
Inflammatory Bowel Disease Treatment Global Market Report 2025
Non Steroidal Anti Inflammatory Drugs Global Market Report 2025
Anti Inflammatory Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
